Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
A clinical-stage biopharmaceutical company developing novel therapies for kidney diseases and related chronic conditions.
Alebund Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe kidney diseases, based in Shanghai, China. The organization operates a vertically integrated platform that targets chronic conditions such as diabetic kidney disease, focal segmental glomerulosclerosis, and hyperphosphatemia, supported by a dedicated small molecule manufacturing facility in Yangzhou. The enterprise has secured significant capital across multiple financing rounds to advance its clinical pipeline, including a $60 million Series B, a $54.5 million Series B+, and a 550 million RMB (approximately $75 million) Series C first closing in January 2025. Its drug development and regional commercialization efforts are backed by prominent venture capital firms such as Lilly Asia Ventures, Quan Capital, Sherpa Healthcare Partners, and Morningside Ventures. Alebund Pharmaceuticals was founded in 2018 by co-founders Gavin Xia and Jin Tian.
Alebund Pharmaceuticals has raised $60.0M across 1 funding round.
Alebund Pharmaceuticals has raised $60.0M in total across 1 funding round.
Alebund Pharmaceuticals has raised $60.0M in total across 1 funding round.
Alebund Pharmaceuticals's investors include Quan Capital, 3E Bioventures Capital, Lilly Asia Ventures, Med-Fine Capital, Sherpa Healthcare Partners.
Alebund Pharmaceuticals has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series B in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 10, 2021 | $60M Series B | Quan Capital | 3E Bioventures Capital, Lilly Asia Ventures, MED Fine Capital, Sherpa Healthcare Partners | Announced |